Trials / Completed
CompletedNCT00036543
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,000 (planned)
- Sponsor
- Abbott · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atrasentan |
Timeline
- Start date
- 2001-05-01
- First posted
- 2002-05-13
- Last updated
- 2006-08-15
Locations
232 sites across 18 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00036543. Inclusion in this directory is not an endorsement.